Amyris Inc (STU:3A01)
€ 0.055 0 (0%) Market Cap: 692,000.00 Enterprise Value: - PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Amyris Inc at Jefferies Consumer Conference (Virtual) Transcript

Jun 23, 2021 / 07:15PM GMT
Release Date Price: €13.33 (+1.06%)
Edlain Rodriguez
Jefferies Financial Group Inc. - Analyst

Okay. Thank you, guys, for joining us and welcome to the Amyris fireside chat with President and CEO, John Melo. I am Edlain Rodriguez from the Jefferies chemicals team. So without further ado, let's get started.

So, John, Amyris has one of the longest histories in synthetic biology, and you are flagged being capable of producing more than 250 molecules from 15 chemical families and over 20 biological pathways. But how would you differentiate Amyris' core approach from companies such as DSM, Genematics, Ginkgo? Like, what are the trade-offs for vertical integration all the way to the consumer brands?

John Melo
Amyris, Inc. - Director, President & CEO

Great. First of all, Edlain, very nice to be on this with you, and appreciate the invitation. Look, I'd say it's interesting, the names of the companies you just chose. Because I think some of them are academic, talking about a vision they haven't yet executed. And others are really significant, fantastic at synthetic biology and really very

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot